6 unchanged sentences
The aggregate offering price for shares sold in the IPO was approximately $118.8 million, resulting in aggregate net proceeds of approximately $107.9 million, after deducting the underwriting discounts, commissions and offering expenses paid or payable by us.
−Removed: None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates.
+Added: No offering expenses were paid or payable, directly or indirectly, to our directors, officers, persons owning 10% or more of any class of our equity securities, or to any of our affiliates.
Goldman Sachs & Co.
−Removed: LLC, Morgan Stanley, Stifel and RBC Capital Markets acted as joint book-running managers for the IPO.
−Removed: There has been no material change in the planned use of proceeds from the IPO from those described in the Prospectus, dated April 4, 2024, filed with the SEC on April 8, 2024, pursuant to Rule 424(b) of the Securities Act.
+Added: LLC, Morgan Stanley & Co.
+Added: LLC, Stifel Nicolaus & Company, Incorporated and RBC Capital Markets, LLC acted as joint book-running managers for the IPO.
+Added: There has been no material change in the planned use of proceeds from the IPO from those described in the final Prospectus, dated April 4, 2024, filed with the SEC on April 8, 2024, pursuant to Rule 424(b) of the Securities Act.
(c) Issuer Purchases of Equity Securities.
3 unchanged sentences
Other Information.
−Removed: From time to time, our officers (as defined in Rule 16a - 1 (f) of the Exchange Act) and directors may enter into Rule 10b5 - 1 or non-Rule 10b5 - 1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K).
−Removed: During the three months ended September 30, 2024, none of our officers or directors adopted or terminated any such trading arrangements except as set forth below:
−Removed: (Title) Action Taken
−Removed: (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities
−Removed: Carmine Stengone
−Removed: ( President and Chief Executive Officer )
−Removed: ( August 19, 2024 ) Rule 10b5 - 1 trading arrangement* Sale Until November 19, 2025 , or such earlier date upon which all transactions are completed or expire without execution Up to 250,980 shares
−Removed: ( Chief Financial Officer )
−Removed: ( August 19, 2024 ) Rule 10b5 - 1 trading arrangement* Sale Until November 19, 2025 , or such earlier date upon which all transactions are completed or expire without execution Up to 41,780 shares
−Removed: Daniel Lorrain, Ph.D.
−Removed: ( Chief Scientific Officer )
−Removed: ( August 19, 2024 ) Rule 10b5 - 1 trading arrangement* Sale Until November 19, 2025 , or such earlier date upon which all transactions are completed or expire without execution Up to 188,325 shares
−Removed: Stephen Huhn, M.D.
−Removed: ( Chief Medical Officer and Senior Vice President, Clinical Development )
−Removed: ( August 19, 2024 ) Rule 10b5 - 1 trading arrangement* Sale Until November 19, 2025 , or such earlier date upon which all transactions are completed or expire without execution Up to 47,300 sha res
−Removed: ( General Counsel and Corporate Secretary )
−Removed: ( August 20, 2024 ) Rule 10b5 - 1 trading arrangement* Sale Until November 19, 2025 , or such earlier date upon which all transactions are completed or expire without execution Up to 11,328 shares
−Removed: Lori Lyons-Williams
−Removed: ( August 21, 2024 ) Rule 10b5 - 1 trading arrangement* Sale Until November 19, 2025 , or such earlier date upon which all transactions are completed or expire without execution Up to 11,784 shares
−Removed: * Intended to satisfy the affirmative defense of Rule 10b5 - 1 (c)
+Added: Trading Arrangements
+Added: During the quarter ended March 31, 2025 , none of our directors or officers adopted or terminated any Rule 10b5 - 1 trading arrangement or any non-Rule 10b5 - 1 trading arrangement (as such terms are defined pursuant to Item 408 (a) of Regulation S-K).
Incorporated by Reference
2 unchanged sentences
Amended and Restated Bylaws of the Registrant.
+Added: Advisor Agreement, dated May, 31, 2024, by and between the Registrant and Diego Miralles.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
Contineum Therapeutics, Inc.
−Removed: November 6, 2024
/s/ Carmine Stengone
Carmine Stengone
−Removed: President and Chief Executive Officer
+Added: President, Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: November 6, 2024
/s/ Peter Slover
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.